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Abstract
Background: Visfatin is an adipokine associated with glucose and lipid metabolism. We previously reported two
visfatin upstream single nucleotide polymorphisms (SNPs), c.-3187G > A (rs11977021) and c.-1537C > T (rs61330082),
which were in perfect linkage disequilibrium, in a Singaporean cohort of severely obese children and are associated
with visfatin level and adverse cardiometabolic parameters. We aim to functionally characterize the effect of c.-
3187G > A and c.-1537C > T SNPs on basal transcriptional activity.
Methods: A 1.6 kb and 3.7 kb upstream promoter region of the visfatin gene was amplified by polymerase chain
reaction and separately cloned into luciferase reporter vectors. Successful clones were transfected into human embryonic
kidney (HEK293T) and human breast carcinoma (MCF7) cells and in-vitro dual-luciferase assay was performed.
Electrophoretic mobility shift assay (EMSA) was also conducted to examine the binding affinity between transcription
factors and visfatin promoter sequences.
Results: Variant promoter with only c.-1537C > T SNP did not show a change in transcriptional activity as compared to
the wild type. However, variant promoter with both c.-3187G > A and c.-1537C > T SNPs showed a statistically significant
increase of 1.41 fold (p < 0.01) in transcriptional activity. The longer 3.7kbp visfatin promoter sequence was also shown to
have significantly higher transcriptional activity (p < 0.05) as compared to the shorter 1.6kbp visfatin promoter. Both c.-
3187G > A and c.-1537C > T variants showed an increased binding with nuclear protein.
Discussion and conclusions: We have demonstrated for the first time that visfatin variant promoter with both c.-
3187G > A and c.-1537C > T SNPs result in an increase in transcriptional activity. This supports our previous finding and
postulation that these SNPs contribute to elevated visfatin levels which may mediate higher triglyceride levels, severe
systolic blood pressure and severe hypertension in obese children. These SNPs may co-operatively affect enhancer or
silencer function to regulate transcriptional activity. In conclusion, this study shows that upstream visfatin SNPs could
potentially affect phenotypic outcome in obese children through alteration of circulating visfatin level.
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Background
Visfatin is an adipokine secreted by adipose tissues [1]
and plasma visfatin was shown to correlate with obesity
and inflammation [2, 3]. The human visfatin gene
(NC_000007.13) is mapped at 7q22.3 on the long arm of
chromosome 7, it spans at an approximate length of
34.7kbp and consists of 11 exons and 10 introns [4]. The
upstream promoter sequence of visfatin contains multiple
binding sites for transcription factors such as nuclear
factor-1 (NF-1), activator protein (AP-1 and AP-2), speci-
ficity protein-1 (SP-1) and glucocorticoid receptor (GR)
[4]. Studies have identified several common upstream sin-
gle nucleotide polymorphisms (SNPs) found to be associ-
ated with inflammation and parameters of glucose and
lipid metabolism [5–8]. Among the reported upstream
SNPs, the c.-1537C > T SNP (rs61330082) has been
shown to cause a reduction in the transcriptional activity
of luciferase reporter assay [9, 10]. However, another
study by Tokunaga et al. found no difference in reporter
gene expression between C and T allele of c.-1537C > T
SNP [11]. Our group has previously reported perfect link-
age disequilibrium between rs61330082 and another SNP,
c.-3187C > T (rs11977021) which was found to be signifi-
cantly associated with total plasma cholesterol and LDL-
cholesterol levels in French-Canadian subjects [5]. These
two SNPs were also shown to be associated with obesity,
severe systolic blood pressure, severe hypertension,
plasma visfatin and triglyceride levels in our cohort of
local severely obese children [12]. We hypothesized that
the two upstream promoter SNPs (rs61330082 and
rs11977021) may have a functional effect on the tran-
scriptional activity of the visfatin gene.
Methods
PCR, cloning and construction of visfatin plasmid
Polymerase chain reaction (PCR) was performed to amp-
lify the upstream promoter region of visfatin. The DNA
samples of unrelated obese subjects identified to be homo-
zygous for the respective wild-type and variant alleles of
the 2 SNPs (rs61330082 and rs11977021) at perfect link-
age disequilibrium were used for PCR [12]. The primers
used to amplify an amplicon of 3.7kbp upstream from
start codon ATG of visfatin gene were 5’-GTA CTC GAG
GCC GGT TAG GAG AGT GCA GCA CAG-3’ (forward)
and 5’- GAA CTA AGA TCT CTC GGG CCG GAG
GAC AGG GGC -3’(reverse). The primers used to amplify
an amplicon of 1.6kbp upstream were 5’-GAC CTC GAG
TGT TTC AAA CCT CGT TGC T-3’ (forward) and 5’-
GAA CTA AGA TCT CTC GGG CCG GAG GAC AGG
GGC -3’(reverse). The visfatin insert was then cloned into
pGL4.10 luciferase reporter vector [Promega, USA]
through BglII and XhoI restriction enzyme digestion. Suc-
cessful clones were obtained and random variants in the
clones were rectified by site-directed mutagenesis. The
sequences of all plasmids were verified by DNA sequen-
cing to ensure no other mutations were present
(Additional files 1 and 2: Figures S1 and S2).
Cell transfection and luciferase assays
Human embryonic kidney cells, HEK293 and human breast
cancer cells (MCF-7) were grown to 90% confluency. The
seeding density of the cells was ~5 × 104 cells/well and they
were pre-cultured in 24-well tissue culture plate for 24 h.
Cells were co-transfected with 1 ng/μl of visfatin
pGL4.10 luciferase plasmid and 0.025 ng/μl of Renilla lu-
ciferase reporter vector using 0.03 μl /μl of Lipofecta-
mine 2000 [Invitrogen, USA]. The transfected cells were
incubated at 37 °C with 5% CO2 overnight for 24 h be-
fore they were used for luciferase assay study. The func-
tionality of the visfatin insert was determined by dual-
luciferase reporter assay [Promega, USA] according to
manufacturer’s instructions. The assay for each visfatin
insert was performed in triplicates and the experiment
was performed thrice. All the 3 transfection experiments
showed similar fold-change. However, due to the vari-
able transfection efficiency, we presented the transfec-
tion results as the mean and SD of the triplicates in one
experiment setting. The results for other 2 biological
replicates are shown in Additional file 3: Figure S3.
Prediction of the functional consequences of the variants
We investigated whether the promoter variants have any
effect on putative transcription factor binding sites within
the visfatin gene using PROMO. The parameters used in
ALGGEN-PROMO program were “only human factors”
and “only human sites”. (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3, last
accessed on 30th May 2014) [13, 14]. MotifMap was
also used to check the nucleotide sequence of the tran-
scription factor binding sites.
Electrophoretic mobility shift assay (EMSA)
We extracted nuclear protein from cultured MCF7 cells
using the NE-PER nuclear and cytoplasmic extraction kit
according to manufacturer’s instructions [ThermoFisher
Scientific, USA]. Biotin-labeled probes of the visfatin pro-
moter sequence containing the respective c.-3187G >A and
c.-1537C >T variant were synthesized [Integrated DNA
technologies, USA]. The probes represent a short section
(11 bases) of the visfatin promoter sequence and were de-
signed to include 5 bases before and after the respective
SNP. The probe sequences are c.-3187G: 5’-ACTGAGGT-
CAA-3’; c.-3187A: 5’-ACTGAAGTCAA-3’; c.-1537C: 5’-
AGTGCCTGGTG-3’; C.-1537 T: 5’- AGTGCTTGGTG-3’.
The biotin-labeled probes were incubated with or without
the nuclear protein extract and in the presence or absence
of unlabeled probes. EMSA was carried out using the Light-
Shift chemiluminescent EMSA kit according to
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manufacturer’s instructions [ThermoFisher Scientific,
USA]. The experiment was performed twice (Additional file
4: Figure S4) and the density of each band was quantified
by GeneTool [Syngene, Cambridge, England].
Statistical analyses
Data are expressed as mean ± standard deviation (SD).
The difference in luciferase activity between different vis-
fatin promoter sequences was analyzed by the Student’s t-
test. Paired sample t-test was used to analyze the differ-
ence in EMSA band intensity between wild-type and vari-
ant promoter sequence [SPSS Version 22, USA].
Results
Transcription factor binding sites in visfatin promoter
sequence
We used the transcription factor binding site prediction
program PROMO to predict any alteration in transcription
factor binding affinity in visfatin promoter sequence previ-
ously found to contain single nucleotide polymorphisms
(SNPs), rs61330082 (c.-3187G >A) and rs11977021 (c.-
1537C >T). PROMO predicted the alteration of the tran-
scription factor estrogen receptor-alpha (ER-alpha) binding
site by c.-3187G >A variant while c.-1537C >T variant was
predicted to alter activating protein-2alphaA (AP-2alphaA)
transcription factor binding site as shown in Fig. 1.
Comparison of transcriptional activity between visfatin
promoter variants
The basal transcriptional activity was measured as the in-
vitro luciferase activity of the different visfatin promoter se-
quences in transiently transfected MCF7 and HEK293T
cells as shown in Fig. 2. The transcriptional activity of the
variant 3.7kbp promoter sequence containing both c.-
3187G >A and c.-1537C >T SNPs was 1.27 and 1.41 fold
higher than that of wild-type 3.7kbp promoter in MCF7
and HEK293T cells respectively. The variant 1.6kbp visfatin
promoter sequence containing only c.-1537C >T SNP
showed no significant change in luciferase activity as
compared to wild-type 1.6kbp promoter in both MCF7 and
HEK293T cells. The transcriptional activity of the wild-type
3.7kbp promoter sequence was 1.08 and 1.13 fold (p =
0.014) higher than that of wild-type 1.6kbp promoter in
MCF7 and HEK293T cells respectively. The transcriptional
activity of the variant 3.7kbp promoter sequence was 1.27
and 1.48 fold higher than that of variant 1.6kbp promoter
in MCF7 and HEK293T cells respectively. The luciferase
assay was performed in triplicates (n = 3) for each promoter
sequence and a minimal amount of luciferase activity (0.21
± 0.03 and 0.27 ± 0.02) was detected in HEK293T and MCF
cells transfected with control pGL4.10 luciferase plasmid.
Binding of transcription factors to visfatin variant
promoter sequence
EMSA data showed that the variant alleles in the respect-
ive c.-3187G >A and c.-1537C > T SNPs have a significant
increased binding with nuclear protein (Fig. 3a, b). The
binding between the visfatin variant promoter sequence
and nuclear protein is assessed by densitometry and the
large standard deviation values were due to comparison
between 2 separate EMSA experiments (Fig. 3c).
Discussion and conclusion
In this study, we functionally characterized two upstream
visfatin promoter SNPs, c.-3187G >A (rs11977021) and c.-
1537C >T (rs61330082), that were previously detected in
the upstream promoter region of visfatin gene in our cohort
of severely obese children [12]. Through the use of the tran-
scription factor binding site prediction program PROMO,
the c.-3187G >A and c.-1537C >T SNPs in the visfatin pro-
moter were predicted to alter the ER-alpha and AP-2alphaA
transcription factor binding sites respectively (Fig. 1). Wang
et al. reported that the c.-1537C >T SNP altered promoter
binding to AP-1 [9] but the study did not examine the pro-
moter binding affinity to AP-2alpha2 which can also be a
likely transcription factor that is affected by the c.-1537C >
T SNP due to the homology between the promoter se-
quence and AP-2alphaA as predicted by PROMO.
Fig. 1 Promoter region of visfatin gene. The sequence representing the ER-alpha and AP-2alphaA transcription factor binding sites located
respectively at −3187 and −1537 of the visfatin promoter region as predicted by PROMO are shown
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The 3.7kbp visfatin variant promoter sequence contain-
ing both c.-3187G > A and c.-1537C > T SNPs was shown
to have a significantly higher luciferase activity than that
of the wild-type 3.7kbp promoter (Fig. 2). This indicated
that the 3.7kbp variant promoter has an increased tran-
scriptional activity and this is in accordance with our pre-
vious finding that the two SNPs were associated with
elevated serum visfatin (6.17 ± 0.76 ng/ml vs. 3.92 ±
0.44 ng/ml) in our cohort of severely obese children [12].
In addition, we examined the transcriptional activity of
the 1.6kbp variant visfatin promoter containing only c.-
1537C > T SNP and found that there is no significant
difference in transcriptional activity as compared to
wild-type 1.6kbp promoter (Fig. 2). Our finding is similar
to that reported by Tokunaga et al. who also found no
difference in transcriptional activity between variant
1.6kbp visfatin promoter containing c.-1537C > T SNP
and wild-type 1.6kbp promoter [11]. However, this dif-
fers from the reports by Wang et al. and Ye et al. who
showed that c.-1537C > T SNP was associated with lower
transcriptional activity [9, 10]. This difference may be at-
tributed to the length of promoter sequence included in
the luciferase reporter assay. While Wang et al. and Ye
et al. have included ~216 bp and ~147 bp of the visfatin
promoter sequence respectively [9, 10], our study has in-
cluded a ~1.6kbp promoter sequence upstream of the
A
B
Fig. 2 Basal transcriptional activity of visfatin promoter variants as measured in-vitro by luciferase assay. The average relative transcriptional activities of
the visfatin promoter variants in a HEK293T and b MCF7 cells are indicated in shaded bars and the standard deviation (SD) is represented by the error
bars. The p-values for the comparison of in-vitro transcriptional activity between the promoter sequences are stated. c.-3187*c.-1537 indicates a 3.7kbp
promoter sequence containing both c.-3187 and c.-1537 SNPs, while c.-1537 indicates a 1.6 kbp promoter sequence containing only c.-1537 SNP
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ATG start codon similar to that in the paper by
Tokunaga et al. [11]. The putative upstream promoter
region of visfatin gene has been shown to contain mul-
tiple transcription factor binding sites [4]. Hence, a full
promoter sequence from the ATG start site may account
for the effect of other transcription factors on the tran-
scriptional activity of the promoter.
The longer 3.7kbp wild-type visfatin promoter was
found to have a significantly higher transcriptional ac-
tivity as compared to the shorter 1.6kbp wild-type
promoter. Moreover, the longer 3.7kbp variant pro-
moter was also found to exhibit a higher transcrip-
tional activity as compared to the shorter 1.6kbp
variant promoter (Fig. 2). Though the in-vivo signifi-
cance of this finding is unclear, we speculate that it
might imply that the longer 3.7kbp region is more
representative of the putative promoter. The higher
transcriptional activity of the wild-type 3.7kbp
promoter may also contribute in part to the accentu-
ated in-vitro activity of 3.7kbp variant promoter. In
addition, the two SNPs, c.-3187G > A and c.-1537C >
T, at perfect linkage disequilibrium may have com-
binatorial effect on the transcriptional activity of the
promoter as it has been shown that variants at link-
age disequilibrium located at multiple enhancer sites
may cooperatively dictate transcript expression [15].
Therefore, unlike previous studies which only examine
the effect of c.-1537C > T SNP, our study takes into
account distal promoter variants that may have com-
binatorial effect on the transcriptional activity of the
promoter.
Both c.-3187G > A and c.-1537C > T SNPs have been
reported as expression quantitative trait loci (eQTLs) in
left ventricular heart tissue with trends of decreasing
expression as the genotype changes from homozygous




Fig. 3 Binding of transcription factors to visfatin promoter variants as measured in-vitro by EMSA. a EMSA for c.-3187G > A SNP only, b EMSA for
c.-1537C > T SNP only, c Assessment of binding between visfatin SNPs and nuclear protein, the EMSA band density are indicated in shaded bars
and the standard deviation (SD) between 2 EMSA experiments is represented by the error bars. (1): Wild-type sequence without nuclear protein,
(2): Wild-type sequence with nuclear protein, (3): Wild-type sequence with nuclear protein and unlabeled probe, (4): Variant sequence without
nuclear protein, (5): Variant sequence with nuclear protein, (6): Variant sequence with nuclear protein and unlabeled probe
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However, our results are contrary to that of the re-
ported eQTLs and this may be possibly due to these
SNPs/reported eQTLs having different effects on differ-
ent cell types, resulting in the difference in expression
level. Hence, the choice of cell model should be taken
into consideration when examining the effect of SNPs
on expression level.
Data from our EMSA experiments indicated an in-
creased binding of nuclear protein to the variant A and T
alleles of c.-3187G >A and c.-1537C > T SNPs respectively
(Fig. 3). This supports the increased transcriptional activ-
ity observed in the 3.7kbp visfatin variant promoter se-
quence (Fig. 2). Although c.-1537C > T SNP also showed
an increase in nuclear protein binding, it did not result in
an increase in transcriptional activity. This may be due to
other upstream SNPs at different regions of the promoter
sequence which may cooperatively affect enhancer or si-
lencer function to regulate transcriptional activity.
Since c.-3187G >A does not exist in solitary without c.-
1537C >T in our obese children cohort, we did not
examine the effect of c.-3187G >A SNP alone on the tran-
scriptional activity. Hence, we could not determine if both
SNPs are needed to work cooperatively in order to exert an
effect on transcriptional activity. In addition, we did not
examine the specific transcription factor that is affected by
the c.-3187G >A and c.-1537C >T SNPs respectively.
Hence, we are not able to determine if the SNPs have af-
fected binding with ER-alpha and AP-2alphaA transcription
factors as predicted by PROMO.
In conclusion, we have demonstrated for the first time
that visfatin variant promoter with both c.-3187G >A and
c.-1537C >T SNPs result in increased in-vitro transcrip-
tional activity. This supports our previous finding and pos-
tulation that these SNPs contribute to elevated visfatin
levels which mediate higher triglyceride levels, severe
systolic blood pressure and severe hypertension in obese
children. This study supports the role of these upstream
visfatin SNPs which could potentially affect phenotypic out-
come in obese children through alteration of circulating
visfatin level.
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